Role of teplizumab, a humanized anti-CD3 monoclonal antibody, in managing newly diagnosed type 1 diabetes: an updated systematic review and meta-analysis
Teplizumab has emerged as a potential disease-modifying drug in type 1 diabetes (T1D). This meta-analysis sought to summarize the therapeutic effect of teplizumab in newly diagnosed patients with T1D.